Newsroom
Inflammatix in the news
Inflammatix Adds MedTech Veteran as First General Counsel
October 10, 2024
Inflammatix Raises $57M in Series E Financing
September 12, 2024
Inflammatix collects $57M as it awaits FDA review of infectious disease test
September 12, 2024
Targeting FDA OK for its test against deadly sepsis, South Bay company raises $57 million
September 12, 2024
Rapid Tests Continue Push Into Sepsis Market in 2023 as Competition Heats Up
January 2, 2024
Inflammatix sepsis test scores FDA breakthrough device designation
November 28, 2023
Inflammatix Aims for 2024 Launch of 30-Minute Sepsis and Acute Infection Test
November 28, 2023
Your medical devices are getting smarter. Can the FDA keep them safe?
October 9, 2023
Press releases
November 11, 2021
Inflammatix Awarded $1.7 Million Grant From National Institutes of Health (NIH)
March 16, 2021
Inflammatix Secures $102 Million in Series D Financing Led by D1 Capital Partners to Commercialize Novel Host Response Diagnostics
October 29, 2020
Inflammatix Announces $7.4 Million in Additional BARDA Funding to Advance ViraBac EZ Acute Infection Test
September 29, 2020
DARPA Awards Inflammatix up to $1.1 Million to Develop Diagnostic that Predicts COVID-19 Severity Risk
April 29, 2020
Study Demonstrates Substantial Cost Savings in Health Economic Model of the Inflammatix Host-Response Test for Sepsis
April 16, 2020
Inflammatix Appoints João Fonseca, Ph.D., as Chief Technology Officer
March 18, 2020
Leading Stanford Alumni Scientists and Physicians Launch StartX Med COVID-19 Task Force
March 4, 2020
New Inflammatix Study in Nature Communications Outlines Breakthrough in Diagnosing Acute Infections by Reading the Immune System
Machine learning blogs
Podcasts
Diagnosing Infection with Ljubomir Buturovic from Inflammatix
December 2023
Advances in Sepsis Diagnostics: the HostDx Sepsis Platform
May 2018